Molecular variants of human papillomavirus types 16 and 18 preferentially associated with cervical neoplasia
Molecular variants of human papillomavirus types 16 and 18 preferentially associated with cervical neoplasia
复制标题
DOI：
10.1099/0022-1317-81-12-2959
复制
发表时间：
2000-12-01
影响因子：
3.8
通讯作者：
Franco, EL
中科院分区：
文献类型：
--
作者：
Villa, LL;Sichero, L;Franco, EL
为了确定人乳头瘤病毒 (HPV) 16 型和 18 型分离株中可能与病变发展相关的地理相关型内变异，对正在进行的 HPV 感染自然过程和宫颈肿瘤的队列研究的数据进行了分析。通过 PCR 进行 HPV 检测，并通过长控制区的序列分析以及 E6 和 L1 基因的点印迹杂交来表征这些 HPV 的分子变异。对 1993 年至 1997 年间参加癌症筛查计划的 1690 名女性的多个第一年样本进行了 HPV 检测。对受试者进行细胞学和宫颈造影随访，以检测宫颈病变。在 65 名受试者的一份或多份样本中检测到 7 种 HPV-16 变种和 4 种 HPV-18 变种。在每个持续感染病例的不同访问中采集的标本中都发现了相同的变异。总体而言，非欧洲变体往往更频繁地持续存在[比值比 (OR) = 4.5；相对于非致癌 HPV 持续存在的风险，95% 置信区间 (CI)，1.6-12.4] 比欧洲 (E) 变体（OR = 2.5；95% CI，1.3-4.9）高。此外，非 E 变异与流行风险（年龄和种族调整 OR = 172.2；95% CI，47.1-630.1）和事件风险更密切相关[相对风险 (RR) = 22.5； 95% CI, 6.0-83.9] 相对于 HPV 阴性女性的风险，高级病变高于 E 变异（普遍病变 OR = 46.3；95% CI，15.5-138.0 和偶发病变 RR = 6.1；95% CI，1.3-27.4）。尽管一致，但后者差异不具有统计显着性。如果在其他人群中得到证实，HPV-16 和 -18 型内变异的测量有可能作为宫颈癌筛查的辅助工具。
In order to determine geographically related intratypic variation in human papillomavirus (HPV) type 16 and 18 isolates that could be associated with lesion development, data were analysed from an ongoing cohort study of the natural course of infection of HPVs and cervical neoplasia. Testing for HPVs was carried out by PCR and molecular variants of these HPVs were characterized by sequence analysis of the long control region and by dot blot hybridization of the E6 and L1 genes. Tests for HPV were done in multiple first-year specimens from 1690 women enrolled in a cancer screening program from 1993 to 1997. Subjects were followed-up by cytology and cervicography for detection of cervical lesions. Seven variants of HPV-16 and four of HPV-18 were detected in one or more specimens from 65 subjects. The same variant was found in specimens taken on different visits from each case of persistent infection. Overall, non-European Variants tended to persist more frequently [odds ratio (OR) = 4.5; 95% confidence interval (CI), 1.6-12.4] than European (E) variants (OR = 2.5; 95% CI, 1.3-4.9), relative to the risk of persistence for non-oncogenic HPVs. In addition, non-E variants were more strongly associated with risk of both prevalent (age- and race-adjusted OR = 172.2; 95% CI, 47.1-630.1) and incident [relative risk (RR) = 22.5; 95% CI, 6.0-83.9] high-grade lesions than E variants (prevalent lesions OR = 46.3; 95% CI, 15.5-138.0 and incident lesons RR = 6.1; 95% CI, 1.3-27.4), relative to the risk for HPV-negative women. Although consistent, the latter differences were not statistically significant. If confirmed in other populations, measurement of intratypic variation of HPV-16 and -18 has the potential to serve as an ancillary tool in cervical cancer screening.